Abstract: A heavy oil is hydrorefined using a hydrorefining catalyst. A spent hydrorefining catalyst whose activity has decreased is heat treated (S1) and pulverized to obtained a regenerated powder (S2). This regenerated powder is fractionated according to its metal content (S3), formed (S6), dried (S7), and calcined (S7) to manufacture a regenerated catalyst whose volume of pores with a diameter of 50 to 2000 nm is at least 0.2 ml/g, and whose volume of pores with a diameter over 2000 nm is no more than 0.1 mL/g. Using this regenerated catalyst, a heavy oil containing at least 45 wt ppm vanadium and nickel as combined metal elements is hydrodemetalized, and the vanadium and nickel are recovered from the used regenerated catalyst (SS1). Through hydrorefining, the metal components are recovered more efficiently, and the spent catalyst can be reused to manufacture a regenerated catalyst that exhibits high reaction, activity.

Abstract: There is provided a catalyst for a fuel electrode of a solid polymer fuel cell, wherein the catalyst comprises fine precious metal particles loaded on a support composed of an electrically conductive material, and wherein the weight ratio of the fine precious metal particles and the support composed of an electrically conductive material (fine precious metal particles:electrically conductive material) is 60:40 to 95:5; and the fine precious metal particles satisfy the following conditions (a) to (c): (a) the fine precious metal particles contain platinum and ruthenium, and the mixing ratio thereof (platinum:ruthenium) is within a range between 1:1 and 1:3 in terms of molar ratio; (b) the fine precious metal particles have an average particle diameter of 3 to 10 nm; and (c) the fine precious metal particles contain oxygen, and the weight ratio of the fine precious metal particles and oxygen (fine precious metal particles:oxygen) is 86:14 to 96:4.

Abstract: An object of the present invention is to provide a photocatalytic powder containing titanium dioxide fine particles containing an anionically active substance, where the electrokinetic potential of the fine particle is from about ?100 to 0 mV in an aqueous environment at pH 5. Another object of the present invention is to provide a photocatalytic slurry containing the powder, and a polymer composition, a coating agent, a photocatalytic functional molded article and a photocatalytic functional structure using the powder.

Abstract: This invention relates to a process and the product thereof for preparing, a molecular sieve catalyst composition, comprising a mixture of: a first quantity of molecular sieve particles, having an 8-ring or larger structure, and a pore size of from about 3 angstroms to about 15 angstroms; and a second quantity of metal carbonate particles; the mixture having been calcined at a temperature of at least about 200° C. for at least about 1 second.

Abstract: A novel technique that is able to efficiently remove, in addition to pentavalent arsenic, trivalent arsenic that has been considered to be difficult to remove. By using a manganese oxygen compound which is characterized by being a product of burning or heating which comprises an oxygen compound of bismuth and an oxygen compound of manganese and by containing manganese as a major component, an aqueous arsenic solution is treated to adsorptively remove the arsenic.

Abstract: A zirconium-loaded fibrous adsorbent material having phosphoryl groups which is produced by first grafting a reactive monomer having phosphoryl groups onto a polymeric substrate and then loading zirconium.

Abstract: A reversible thermochromic display article which comprises a substrate and, formed thereon, a heat coloration image containing a heat coloration type reversible thermochromic composition which is colored by heating and is decolored by cooling and a heat decoloration image containing a heat decoloration type reversible thermochromic composition which is decolored by heating and is colored by cooling, or having a multilayer structure comprising a heat coloration layer containing the heat coloration type reversible thermochromic composition and a heat decoloration layer containing the heat decoloration type reversible thermochromic composition, wherein the heat coloration type reversible thermochromic composition is a microcapsule composition which contains, enclosed therein, (a) an electron-donating chromatic organic compound, (b)? an electron-accepting compound selected from gallic acid esters, and (c) a reaction medium having a melting point lower than 50° C.

Abstract: Novel organoammonium compounds are provided, which are useful as additives for improving the antiwear and friction-reducing properties of lubricating compositions. The compound is formed by reacting a metal acid hydrate with one or more alkyl amines. Particular examples are the preparation of ditridecylammonium tungstate, di-n-octylammonium tungstate and ditridecylammonium molybdate.

Abstract: A darkly colored article especially suitable for cleansing skin having the general form of a fibrous bar is described. The article includes a solid or semi-solid lathering composition that at least partially incorporates a continuous fabricated polymeric network. By including a network that has a CIE Lightness Value of less than about 50, especially an achromatic network, darkly colored cleansing articles can be provided that have minimum staining potential and exhibit good color stability during storage and use.

Abstract: The products of the invention are polymers of carboxylated alkylpolyglycosides. The products are very mild surfactants that are useful in personal care applications.

Abstract: Disclosed is a cleaning composition for removing ink from a variety of surfaces, but more particularly from rubber. The composition has a high evaporation rate, is completely biodegradable, environmentally safe, not harmful to rubber, and has a near neutral pH.

Abstract: The present invention relates to support-fixed bleaching catalyst(s)suitable or the catalysis of peroxide compounds, characterized in that the support-fixed bleaching catalyst(s) is/are covalently bonded to a support by means of at least one organic ligand of the bleaching catalyst. The bleaching catalyst(s) form(s) a complex with at least on transition metal. The invention further relates to support-fixed bleaching catalysts for the catalysis of peroxide compounds, where at least one ligand, covalently bonded to a support, is a transition-metal-free ligand, which chelates with transition metal, derived from another source, preferably from the bleaching composition and/or added water and thus forms the complex with a transition metal.

Abstract: The invention is directed to aqueous liquid laundry detergent compositions for cleaning and imparting fabric care benefits to fabrics laundered therewith. Such compositions comprise (A) at least one detersive surfactant; (B) droplets of a silicone blend comprising a nitrogen-containing amino or ammonium functionalized polysiloxane and a nitrogen-free non-functionalized polysiloxane; and (C) at least one additional non-silicone laundry adjunct selected from detersive enzymes, dye transfer inhibiting agents, optical brighteners, suds suppressors and combinations thereof. The functionalized polysiloxane component of the silicone blend has a relatively low, i.e., less than 30 mol %, content of reactive/curable groups, a nitrogen content which ranges from 0.05% to 0.30% by weight and a viscosity which ranges from 0.00002 m2/s to 0.2 m2/s. The nitrogen-free non-functionalized polysiloxane material ranges in viscosity from 0.01 m2/sec to 2.0 m2/sec.

Abstract: The present invention relates to personal treatment compositions, which contain encapsulated perfume compositions, which release a burst of fragrance a period of time after initial topical application. According to the present invention, the burst of fragrance is released with the application of mechanical pressure on the encapsulated perfume composition. Further, the present invention relates to hair and skin compositions, which release a burst of fragrance a period of time after initial topical application by rubbing the skin or brushing the hair.

Abstract: The present invention provides novel beta-secretase inhibitors and methods for their use, including methods of treating of Alzheimer's disease.

Abstract: In one embodiment, the invention provides a method for detecting increased risk of vulvovaginal candidiasis or vulvur vestibulitis syndrome. The method comprises obtaining a biological sample and determining whether a mutant allele of mannose-binding lectin gene is present in the sample. In another embodiment, the invention provides a method for treating or preventing vulvovaginal candidiasis or vulvur vestibulitis syndrome in a female in need thereof. The method comprises administering an effective amount of a mannose-binding lectin protein.

Abstract: Use of plasma proteins concentrates containing VWF with a high proportion of high molecular weight multimers prevents a bleeding diathesis and reduces pre-, peri- and postoperative blood loss in acquired Von Willebrand syndromes such as in cardiovascular diseases requiring surgical procedures, especially those requiring extracorporeal circulation.

Abstract: Methods are provided for enhancing the death of a neaplastic cell comprising the administration of a therapeutically effective concentration of a 14-3-3 antagonist and at least one antineoplastic therapeutic agent. The methods of the invention find use in improving the clinical outcome of a mammal having a neoplastic disorder and comprises administration to a mammal in need thereof at least one antineoplastic therapeutic agent in combination with a 14-3-3 antagonist. Further provided are pharmaceutical compositions having a therapeutically effective amount of a 14-3-3 antagonist and an antineoplastic therapeutic agent. Also provided are methods for identifying agents that selectively inhibit an interaction between a 14-3-3 polypeptide and a 14-3-3 ligand.

Abstract: The present invention provides polynucleotides, polypeptides, pharmaceutical compositions, and methods for modulation of nerve growth and regeneration.

Abstract: The invention provides compositions and methods for treating, preventing, and diagnosing diseases or conditions associated with an abnormal level or activity of biglycan; disorders associated with an unstable cytoplasmic membrane, due, e.g., to an unstable dystrophin associated protein complex (DAPC); disorders associated with abnormal synapses or neuromuscular junctions, including those resulting from an abnormal MuSK activation or acetylcholine receptor (AChR) aggregation. Examples of diseases include muscular dystrophies, such as Duchenne's Muscular Dystrophy, Becker's Muscular Dystrophy, neuromuscular disorders and neurological disorders.

Abstract: The invention relates to the prevention and treatment of diseases associated with undesirable cell proliferation comprising preventing and treating mycoplasma and other microorganism co-infection. It is based, at least in part, on the discovery that, in many cases, mycoplasma infection exists coincident with a second microorganism.

Abstract: A highly concentrated, low salt-containing, biologically active syrup form of IGF-I or variant thereof and methods for its preparation are provided. This novel syrup form of IGF-I has an IGF-I concentration of at least about 250 mg/ml, a density of about 1.0 g/ml to about 1.2 g/ml, and a viscosity of about 13,000 centipoise (cps) to about 19,000 cps, as measured at ambient temperature (23° C.). The IGF-I syrup is prepared by precipitating or partitioning IGF-I from solution, preferably by adjusting the solution pH or by use of a solubility enhancer to concentrate IGF-I in solution followed by removal of the solubility enhancer. The precipitated syrup is useful as a means of storing IGF-I in a stable form and as a means of preparing compositions comprising biologically active IGF-I. Pharmaceutical compositions and kits comprising this concentrated IGF-I syrup are provided.

Abstract: The invention provides compositions and methods for treatment of sleep disorders. Such methods entail administering to the patient a therapeutically effective dosage regime of an agonist of a hypocretin 1 (Hcrt-1) receptor to a peripheral tissue of the patient, and monitoring the condition of the patient responsive to the treatment, wherein the monitoring indicates a reduction in excessive daytime sleepiness (EDS) and an improvement in nighttime sleep consolidation and architecture. The methods are particularly useful for prophylactic and therapeutic treatment of one or more sleep disorders in a patient.

Abstract: The present invention relates to novel hair follicle growth factor (HFGF) proteins, genes encoding HFGFs, methods for preparing HFGF proteins and therapeutic uses of HFGF proteins. The HFGF proteins of the present invention have a characteristic reduced expression in hair follicles derived from alopecia patients and have a stimulatory effect on hair follicle cell proliferation. HFGF proteins may be used to prevent or treat alopecia and to promote or accelerate hair growth and hair follicle repair.

Abstract: A method of modulating cytokine mediated hepatic injury by administering compound-D SEQ ID NO:1 to a mammal. A concentration of the compound in the range of about 0.5 mg/kg to about 20 mg/kg in a physiologically acceptable formulation blocks a cytokine cascade. A therapeutic method of modulating cytokine mediated acute inflammatory, trauma induced and toxin induced hepatic injury, particularly via tumor necrosis factor modulation, is thus disclosed.

Abstract: Compositions of purified biologically active Wnt proteins are provided. Wnt proteins are found to be hydrophobic and post-translationally modified by addition of a lipid moiety at a conserved cysteine residue. Methods for isolation of Wnt utilize detergents that maintain the solubility of the modified protein.

Abstract: The present invention relates to novel anti-hypertensive molecules. The present invention also provides a process for the preparation of novel antihypertensive molecules. The present invention particularly relates to the preparation of novel Angiotensin Converting Enzyme Inhibitors (ACEI) with prolonged activity. ACE inhibitors play an important role in Renin-Angiotensin-Aldosteron system (RAAS) by inhibiting the activity of Angiotensin Converting Enzyme (ACE) and therefore are used to regulate blood pressure. ACE inhibitors synthesized by the process of present invention have a peptide moiety and nonpeptide moiety. ACE inhibitors, synthesized by this present invention, show enhanced bioavailability and fewer side effects.

Abstract: The invention relates to compounds for topically influencing the activity of dipeptidyl peptidase of the general formula wherein A is an amino acid having at least one functional group in the side chain; B is a chemical compound covalently bound to a functional group of the side chain of A, chosen from the group consisting of (a) oligopeptides having a chain length of up to 20 amino acids, (b) homopolymers of glycine consisting of up to 6 glycine monomers, and (c) polyethylene glycols having molar masses of up to 20 000 g/mol; and C is a group amide-bonded to A chosen from the group consisting of thiazolidine, pyrrolidine, cyanopyrrolidine, hydroxyproline, dehydroproline or piperidine.

Abstract: The invention provides compositions and methods useful for treating disorders treatable by producing a protein in a regulatable manner in a mucosal cell or tissue of an animal. The treatment methods include in vivo and ex vivo methods, including transplanting in vitro transformed cells that secrete the protein into a mammalian subject.

Abstract: Preventives and/or remedies for liver diseases, which comprise monocyte chemoattractant protein-I (MCP-I) function inhibitors as active ingredients, respectively. Administration of the MCP-I function inhibitors brings about effects in preventing and/or remedying liver diseases.

Abstract: This invention is directed to a method of preventing or treating diseases or conditions associated with platelet aggregation. The method is also directed to a method of treating thrombosis or related disorders. The method comprises administering to a compounds useful for this invention include compounds of general Formulae I and III-XII, or salts, hydrates, and solvates thereof. The present invention also provides novel compounds of Formulae I and III-XII.

Abstract: Invented are non-peptide TPO mimetics. Also invented are novel processes and intermediates used in the preparation of the presently invented compounds. Also invented is a method of treating thrombocytopenia, in a mammal, including a human, in need thereof which comprises administering to such mammal an effective amount of a selected hydroxy-1-azobenzene derivative.

Abstract: There is provided a pharmaceutical composition comprising (i) a compound of the formula wherein: X is a hydrocarbyl ring having at least 4 atoms in the ring; K is a hydrocarbyl group; Rs is a sulphamate group; (ii) optionally admixed with a pharmaceutically acceptable carrier, diluent, excipient or adjuvant, wherein the compound is present in an amount to provide a dosage of no greater than 200 ?g/day.

Abstract: Methods for promoting healthy body weight and improving a variety of related physiological factors, including serum serotonin levels, serum leptin levels, fat oxidation, cholesterol levels, and body mass index, in persons or other mammals, include administering to those persons or other mammals effective amounts of hydroxycitric acid or a combination of hydroxycitric acid, chromium and gymnemic acid, which work synergistically to further to promote healthy body weight and improve these physiological factors.

Abstract: Disclosed are methods for determining the stage of neurofibrillary degeneration associated with a tauopathy in a subject believed to suffer from the disease, by (i) introducing into the subject a ligand capable of labeling aggregated paired helical filament (PHF) tau protein, (ii) determining the presence and/or amount of ligand bound to extracellular aggregated PHF tau in the medial temporal lobe of the brain of the subject, (iii) correlating the result of the determination made in (ii) with the extent of neurofibrillary degeneration in the subject. The methods can be used for pre-mortem diagnosis and staging of tauopathies such as Alzheimer's Disease. Preferred ligands include sulphonated-benzothiazole-like compounds and diaminophenothiazines.

Abstract: Compounds are provided that act as potent antagonists of chemokine receptors. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of chemokine receptor-mediated diseases, and as controls in assays for the identification of chemokine antagonists.

Abstract: PDE4 inhibition is achieved by novel compounds of the Formula I: wherein R1 and R2 are as defined herein.

Abstract: The present invention relates generally to compounds of formula (I): wherein X is a five or six-membered heteroaromatic ring, containing one to four heteroatoms, selected from nitrogen, oxygen, or sulfur, provided that at least one heteroatom is nitrogen; and G1 and G2 are independently CH or N. The present invention also relates to the preparation of the compounds, pharmaceutical formulations thereof, and their use in medicine as potent or selective A2B adenosine receptor antagonists and their uses for treating asthma, autoimmune diseases and retinal vascular diseases.

Abstract: The present invention relates to methods, compounds, and compositions comprising compounds that treat pathophysiological conditions arising from inflammatory responses, and is directed to compounds that inhibit or block glycated protein produced induction of the signaling-associated inflammatory response in endothelial cells. The present invention also relates to compounds that inhibit smooth muscle proliferation, for example, by modulating HSPGs such as Perlecan. The present invention further relates to the use of compounds to treat vascular occlusive conditions characterized by smooth muscle proliferation such as restenosis and atherosclerosis. This invention also relates to medical devices, such as a stent, comprising a compound or composition of this invention disposed on or within the medical device.

Abstract: Disclosed are compounds of formula (I) Where Ar1, X, Y, Q, W, R3, R4, R5, R6 and Ry are defined herein. The compounds of the invention inhibit production of cytokines involved in inflammatory processes and are thus useful for treating diseases and pathological conditions involving inflammation such as chronic inflammatory disease. The compounds are also useful for treating diseases or conditions related to oncology and anticoagulant or fibrinolytic therapy. Also disclosed are processes for preparing these compounds and pharmaceutical compositions comprising these compounds.

Abstract: Methods of treating an SCD-mediated disease or condition in a mammal, preferably a human, are disclosed, wherein the methods comprise administering to a mammal in need thereof a compound of formula (I): where x, y, W, V, R2, R3, R4, R5, R6, R6a, R7, R7a, R8, R8a, R9 and R9a are defined herein. Pharmaceutical compositions comprising the compounds of formula (I) are also disclosed.

Abstract: This invention provides a compound, or its possible salt, having the formula, wherein: Re and ?Re are OH, optionally independently etherified or esterified; Z is —CH2CH2— or —C(R4,R5)—, wherein R4 and R5 are independently H, (1C-2C)alkyl or form together a spiro(3C-5C)cycloalkyl; R1 is H, halogen, CF3, or (1C-4C)alkyl; R2 and R3 are independently H, halogen, —CF3, —OCF3, (1C-8C)alkyl, hydroxy, (1C-8C)alkyloxy, aryloxy, aryl(1C-8C)alkyl, halo(1C-8C)alkyl, —O(CH2)mX, wherein X is halogen or phenyl and m=2-4; —O(CH2)mNRaRb, —S(CH2)mNRaRb or —(CH2)mNRaRb, wherein m=2-4 and wherein Ra, Rb are independently (1C-8C)alkyl, (2C-8C)alkenyl, (2C-8C)alkynyl, or aryl, which alkyl, alkenyl and aryl can optionally be substituted with halogen, —CF3, —OCF3, —CN, —NO2, —OH, (1C-8C)alkoxy, aryloxy, carboxyl, (1C-8C)alkylthio, carboxylate, (1C-8C)alkyl, aryl, aryl(1C-8C)alkyl or halo(1C-8C)alkyl; or Ra and Rb form a 3-8 membered ring structure, optionally substituted with halogen, —CF3, —OCF3, —CN, —NO2, hydroxy, hydroxy(1C-

Abstract: This invention relates to compounds of formula (I) where R1 to R12, —W—V—, —X—Y—, p and n have the values defined in claim 1, their preparation and use as pharmaceuticals for the treatment of central nervous system disorders, such as depression, bipolar disorder, and anxiety.

Abstract: Fungicidal mixtures, comprising A) the triazolopyrimidine of the formula I ?and B) amide compounds of the formula II where X1 and X2 are halogen, nitro, cyano, alkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl, haloalkynyl, alkoxy, haloalkoxy, haloalkylthio, alkylsulfinyl or alkylsulfonyl; x is 1, 2, 3 or 4; and y is 1, 2, 3, 4 or 5; in a synergistically effective amount, methods for controlling harmful fungi using mixtures of the compounds I and II, compositions comprising these compounds and the use of the compounds I and II for preparing such mixtures are described.

Abstract: Protein kinase inhibitors are disclosed having utility in the treatment of protein kinase-mediated diseases and conditions, such as cancer. The compounds of this invention have the following structure: including steroisomers, prodrugs and pharmaceutically acceptable salts thereof, wherein A is a ring moiety selected from: and wherein R1, R2, R3, X, Z, L1, Cycl1, L2 and Cycl2 are as defined herein. Also disclosed are compositions containing a compound of this invention, as well as methods relating to the use thereof.

Abstract: Disclosed are compounds which bind ?4 integrins, where the ?4 integrin is preferably VLA-4. Certain of these compounds also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by ?4 integrins, where the ?4 integrin is preferably VLA-4. Such compounds are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The compounds can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis.

Abstract: A composition and method for cleansing a colon prior to endoscopic procedure. More particularly, a combination of bisacodyl, metoclopramide, sodium, and/or a phosphorus containing composition administered in sequential doses for preparing a colon prior to colonoscopy.

Abstract: This invention is directed to compounds which are selective antagonists for melanin concentrating hormone-1 (MCH1) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of reducing the body mass of a subject which comprises administering to the subject an amount of a compound of the invention effective to reduce the body mass of the subject.

Abstract: Compounds of the Formula: are useful for the treatment of depression (including but not limited to major depressive disorder, childhood depression and dysthymia), anxiety, panic disorder, post-traumatic stress disorder, premenstrual dysphoric disorder (also known as pre-menstrual syndrome), attention deficit disorder (with and without hyperactivity), obsessive compulsive disorder, social anxiety disorder, generalized anxiety disorder, obesity, eating disorders such as anorexia nervosa and bulimia nervosa, vasomotor flushing, cocaine and alcohol addiction, sexual dysfunction and related illnesses.

Abstract: The present invention provides pyrrolo[2,3-b]pyridine-4-yl amines pyrrolo[2,3-b]pyrimidin-4-yl amines that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases and cancer.